BRPI0517272A - derivados de pirimidina bicìclicos de inibição de hiv - Google Patents

derivados de pirimidina bicìclicos de inibição de hiv

Info

Publication number
BRPI0517272A
BRPI0517272A BRPI0517272-1A BRPI0517272A BRPI0517272A BR PI0517272 A BRPI0517272 A BR PI0517272A BR PI0517272 A BRPI0517272 A BR PI0517272A BR PI0517272 A BRPI0517272 A BR PI0517272A
Authority
BR
Brazil
Prior art keywords
substituted
alkyl
amino
optionally substituted
halo
Prior art date
Application number
BRPI0517272-1A
Other languages
English (en)
Inventor
Paul Adriaan Jan Janssen
Jerome Emile Georges Guillemont
Mika L Paugam
Bruno Francois Marie Delest
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0517272A publication Critical patent/BRPI0517272A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE PIRIMIDINA BICìCLICOS DE INIBIçãO DE HIV. Os inibidores de replicação de HIV de fórmula (I) N-óxidos, sais de adição farmaceuticamente aceitáveis, aminas quartenárias ou formas estereolsoméricas destes, em que -a˜=a-a =a¬ 4¬- é -GH=CH-CH=GH-, -N=CH-CHGH-, -N=CH-N=CH-, -NCH- CHN-, -N=N-CH=CH-; -b˜=b-b=b¬ 4¬- e -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=GH-N=CH-, -N=CH-CH=N-, -N=N- GHCH-; n e m é 0,1, 2, 3 e em certos casos também 4; R¬1¬ é hidrogênio;arila; formila; C~ 1-6~alquilcarbonila; C~ 1-6~alquila opcionalmente substituida; C~ 1-6~alquilóxicarbonila; R é OH; halo; C~ 1-6~alquila opcionalmente substituida, C~ 2-6~alquenila ou C~ 2-6~alquinila; carbonila substituida; carboxila; CN; nitro; amino; amino substituído; polialometila; polialometiltio;-S(=O)~ p~R¬ 6¬ ; C(=NH)R¬ 6¬; R¬ 2a¬ é CN; amino; amino substituído; C~ 16~alquila opcionalmente substituida; halo; C~ 1-6~alquiIóxi opcionalmente substituído; carbonila substituida; -CH=N-NH-C(=O)-R¬ 16¬; C~ 1-6~alquilóxiC~ 1-6~aIquila opcionalmente substituida; C~ 2-6~alqueniía ou C~ 2-6~alquiniía substituida; -C(=N-O-R¬ 8¬)-C~ 1-4~alquila; R¬ 7¬ ou -X-R¬ 7¬; R¬ 3¬ é CN; amino; C~ 1-6~aIquila; halo; C~ 1-6~alquiíóxi opcionalmente substituído; carbonila substituida; -CH=N-NH-C(=O)-R¬ 16¬; C~ 1-6~alquiIa substituida; C~ 16~alquilóxiC~ 1-6~alquila opcionalmente substituida; C~ 2-6~alquenila ou C~ 2-6~alquinila substituida; -C(=N-O-R~ 8~)-C~ 1-4~alquila; R¬ 7¬; -X-R¬ 7¬; R¬ 4¬ é halo; OH; C~ 1-6~aIquiIa, C~ 2-6~alquenila ou C~ 2-6~alquinila opcionalmente substituida; C~ 3-7~acicloalquila; C~ 1-6~alquilóxi; CN; nitro; polialoC~ 1-6~alquila; poliaíoC~ 1-6~alquilóxi; carbonila substituida; formila; amino; mono- ou di(C~ 1-4~alquil)amino ou R¬ 7¬; -A-B- é -CR¬ 5¬=N-, -N=N-, -CH~ 2~-CH~ 2~-, -CS-NH-, -CO-N H-, -CH=CH-; composições farmacêuticas compreendem estes, métodos para a preparação destes compostos e composições; o emprego destes compostos para a prevenção ou o tratamento de infecção de HIV.
BRPI0517272-1A 2004-10-29 2005-10-27 derivados de pirimidina bicìclicos de inibição de hiv BRPI0517272A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105419 2004-10-29
PCT/EP2005/055589 WO2006045828A1 (en) 2004-10-29 2005-10-27 Hiv inhibiting bicyclic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0517272A true BRPI0517272A (pt) 2008-10-07

Family

ID=34929789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517272-1A BRPI0517272A (pt) 2004-10-29 2005-10-27 derivados de pirimidina bicìclicos de inibição de hiv

Country Status (16)

Country Link
US (5) US8153640B2 (pt)
EP (1) EP1807430B1 (pt)
JP (1) JP5118972B2 (pt)
KR (1) KR20070085286A (pt)
CN (1) CN101048410B (pt)
AR (1) AR051410A1 (pt)
AU (1) AU2005298637B8 (pt)
BR (1) BRPI0517272A (pt)
CA (1) CA2577588C (pt)
ES (1) ES2508766T3 (pt)
IL (1) IL180963A (pt)
MX (1) MX2007005159A (pt)
RU (1) RU2403254C2 (pt)
TW (1) TW200630370A (pt)
WO (1) WO2006045828A1 (pt)
ZA (1) ZA200703444B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ATE541848T1 (de) 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
EP1991547A2 (en) * 2006-03-09 2008-11-19 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
AU2007309167A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as PKC-theta inhibitors
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
UY31631A1 (es) * 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CN102115452A (zh) * 2009-12-30 2011-07-06 上海特化医药科技有限公司 (e)-3-(3-取代-5-甲基苯基)丙烯腈及其制备方法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011135578A1 (en) 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
US9409914B2 (en) * 2012-01-28 2016-08-09 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
EP2872492B1 (en) * 2012-07-12 2018-01-31 Hetero Research Foundation Process for the preparation of rilpivirine using a novel intermediate
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EP2994471B1 (en) 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles as kinase inhibitors
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
US20160222014A1 (en) * 2013-09-10 2016-08-04 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
CA2972014C (en) 2014-12-24 2019-09-24 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of hiv
SG11201705184PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
EP3270694A4 (en) * 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
US20210380540A1 (en) * 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
CA3158698A1 (en) 2020-02-19 2021-08-26 Alexander Vitalievich Kurkin Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CN111303162B (zh) * 2020-04-16 2021-01-22 天津法莫西医药科技有限公司 一种2-氯-7-环戊基-7H-吡咯并[2,3-d]嘧啶-6-羧酸的制备方法
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
KR20250101955A (ko) * 2023-12-27 2025-07-04 주식회사 에이조스바이오 신규 퓨린계 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE21593C (de) Dr. LÖWIG, Prof. in Breslau Verfahren zur Darstellung von Aetznatron und Aetzkali durch Glühen von Strontiumcarbonat oder Kaliumcarbonat mit Eisenoxyd
DD21593A (pt) *
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
ID28376A (id) * 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
KR100714519B1 (ko) * 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
RU2328497C2 (ru) * 2003-05-05 2008-07-10 Ф.Хоффманн-Ля Рош Аг Конденсированные производные пиримидина и лекарственное средство, обладающее активностью в отношении crf
NZ545058A (en) 2003-07-16 2008-05-30 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation

Also Published As

Publication number Publication date
WO2006045828A1 (en) 2006-05-04
US10077270B2 (en) 2018-09-18
AR051410A1 (es) 2007-01-10
MX2007005159A (es) 2007-06-26
US9487518B2 (en) 2016-11-08
CN101048410A (zh) 2007-10-03
IL180963A (en) 2015-06-30
AU2005298637B2 (en) 2012-06-28
ES2508766T3 (es) 2014-10-16
US20080085907A1 (en) 2008-04-10
CN101048410B (zh) 2010-06-23
US20120190697A1 (en) 2012-07-26
US9802943B2 (en) 2017-10-31
RU2403254C2 (ru) 2010-11-10
TW200630370A (en) 2006-09-01
US20160355519A1 (en) 2016-12-08
JP2008517978A (ja) 2008-05-29
US20180009819A1 (en) 2018-01-11
US20180016281A1 (en) 2018-01-18
US10072015B2 (en) 2018-09-11
US8153640B2 (en) 2012-04-10
JP5118972B2 (ja) 2013-01-16
AU2005298637A8 (en) 2012-12-06
KR20070085286A (ko) 2007-08-27
AU2005298637B8 (en) 2012-12-06
AU2005298637A1 (en) 2006-05-04
ZA200703444B (en) 2008-11-26
EP1807430A1 (en) 2007-07-18
CA2577588A1 (en) 2006-05-04
CA2577588C (en) 2013-09-10
IL180963A0 (en) 2007-07-04
RU2007119784A (ru) 2008-12-10
EP1807430B1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
AU2005298637A8 (en) HIV inhibiting bicyclic pyrimidine derivatives
TW200626560A (en) HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
WO2006035067A3 (en) Hiv inhibiting 5-heterocyclyl pyrimidines
AP1610A (en) HIV replication inhibiting pyrimidines.
TW200510339A (en) HIV replication inhibiting pyrimidines and triazines
BR0213522B1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
UA85541C2 (ru) Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
NO20062150L (no) Nye ketooksadiazolderivater som katepsinhibitorer
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2002038563A3 (en) Condensed pyrazindione derivatives as pde inhibitors
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
EP1747200B8 (en) Alkaloid compounds and their use as anti-malarial drugs
SE0402763D0 (sv) Nitro indazole derivatives
BRPI0416588A (pt) uso farmacêutico adicional
SE0302666D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]